Please ensure Javascript is enabled for purposes of website accessibility

Why Humanigen Stock Is Skyrocketing Today

By Prosper Junior Bakiny - Mar 29, 2021 at 1:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's investigational coronavirus treatment could hit the market soon.

What happened

Shares of clinical-stage biopharmaceutical company Humanigen (HGEN 7.98%) are soaring through the roof on Monday after the company reported positive top-line results from a clinical trial for one of its pipeline candidates, lenzilumab. As of 1:20 p.m. EDT, the company's stock was up by 66.6% after jumping by as much as 108.7% earlier today. 

So what 

Lenzilumab is an experimental treatment for COVID-19. In a phase 3 clinical trial on patients hospitalized with the disease, those who received lenzilumab and other treatments (including steroids and remdesivir, an antiviral medicine for COVID-19 marketed by Gilead Sciences), were 54% more likely to survive without the assistance of mechanical ventilation than those who received a placebo and other treatments.

Microscopic view of the coronavirus.

Image source: Getty Images.

Also, lenzilumab was generally safe and well tolerated during the study. None of the serious adverse reactions observed in the trial were attributed to the medicine. According to Dr. Zelalem Temesgen, the principal investigator of the study, "The data strongly suggest that lenzilumab improved outcomes for hospitalized patients with COVID-19 pneumonia." With these positive results under its belt, Humanigen is gearing up to submit a request for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for lenzilumab.

Now what

Several COVID-19 medicines have already earned Emergency Use Authorization from regulatory authorities, including remdesivir and Eli Lilly's bamlanivimab. But there can never be enough effective treatments for a disease, particularly one that has caused a deadly worldwide pandemic. Lenzilumab looks likely to contribute meaningfully to Humanigen's top line, and given that the healthcare company currently has no products on the market, it is not surprising to see investors bid up its shares today. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Humanigen, Inc. Stock Quote
Humanigen, Inc.
$2.03 (7.98%) $0.15
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$295.19 (-2.06%) $-6.21
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$63.22 (0.06%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.